Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update

R Roskoski Jr - Pharmacological research, 2022 - Elsevier
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21st century. There …

Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.

R Roskoski Jr - Pharmacological Research, 2021 - europepmc.org
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21st century. There …

[引用][C] Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update

R Roskoski Jr - Pharmacological Research, 2022 - cir.nii.ac.jp
Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update

R Roskoski Jr - Pharmacological research, 2022 - pubmed.ncbi.nlm.nih.gov
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21st century. There …

[PDF][PDF] Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update☆

R Roskoski Jr - Pharmacological Research, 2022 - brimr.org
Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21st century. There …